Get the Stockscreener App
1.16
5.45%
0.06
After Hours:
1.15
-0.01
-0.86%
Immunic Inc Stock (IMUX) Latest News
Immunic at Leerink’s Conference: Strategic Moves in MS Treatment - Investing.com
Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April - Proactive financial news
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Analysts - Defense World
Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data - Proactive Investors
Immunic to Participate in Scientific and Investor Conferences in March - Kilgore News Herald
Immunic announces participation in Hamburg and Miami conferences - Proactive Investors USA
Immunic Showcases Dual-Action Drug Research at Major Virology Meeting While Courting Investors - StockTitan
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
Biotechs challenge big pharma with new oral weight loss therapies - Proactive Investors USA
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis - The Malaysian Reserve
Immunic to highlight vidofludimus calcium’s potential as MS therapy at upcoming forum - Proactive Investors USA
Immunic (NASDAQ:IMUX) Receives Buy Rating from HC Wainwright - MarketBeat
How Do Things Look For Immunic Inc (NASDAQ: IMUX) In The Short-Term? - Stocks Register
Immunic's (IMUX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World
Immunic (IMUX) to Release Earnings on Thursday - MarketBeat
Immunic drug candidate may offer new obesity treatmentICYMI - Proactive Investors USA
Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week - Yahoo Finance
H.C. Wainwright maintains Immunic stock Buy rating, $10 target By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains Immunic stock Buy rating, $10 target - Investing.com
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing - The Malaysian Reserve
Market movers: Walmart, Palantir, Immunic, Alibaba… - Proactive Investors UK
Immunic’s IMU-856 shows promise in weight management By Investing.com - Investing.com Nigeria
Immunic highlights IMU-856’s potential as weight management therapy - Proactive Investors Australia
Immunic's IMU-856 shows promise in weight management - Investing.com
Immunic’s IMU-856 shows promise for obesity treatment - Proactive Investors USA
Immunic's IMU-856 shows promise in weight management By Investing.com - Investing.com South Africa
Immunic announces IMU-856 demonstrated dose-dependent increase - TipRanks
Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1 -February 20, 2025 at 07:31 am EST - Marketscreener.com
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat
Pleasing Signs As A Number Of Insiders Buy Immunic Stock - Simply Wall St
Immunic Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Immunic (NASDAQ:IMUX) Downgraded to Sell Rating by StockNews.com - MarketBeat
IMUX stock touches 52-week low at $0.92 amid market challenges - MSN
Breaking Barriers: Immunic CSO marks International Day of Women and Girls in Science - Proactive Investors USA
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Immunic CEO on key MS trial data coming in April - Proactive Investors USA
Immunic Inc (IMUX) Becoming More Attractive for Investors - Knox Daily
Immunic Inc’s results are impressive - US Post News
Market Recap: Immunic Inc (IMUX)’s Negative Momentum, Closing at 0.95 - The Dwinnex
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in January - MarketBeat
Immunic announces attendance at February investor and scientific conferences - Proactive Investors USA
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):